# Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience

> **NCT07031063** · PHASE4 · RECRUITING · sponsor: **Instituto Mexicano del Seguro Social** · enrollment: 124 (estimated)

## Conditions studied

- HIV Infection
- Metabolic Syndrome
- Antiretroviral Treatment

## Interventions

- **DRUG:** DTG/3TC
- **DRUG:** Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)

## Key facts

- **NCT ID:** NCT07031063
- **Lead sponsor:** Instituto Mexicano del Seguro Social
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07031063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07031063, "Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07031063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*